大唐药业(836433) - 2024 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2024 was CNY 38,103,723.62, a decline of 29.72% year-on-year[11] - Net profit attributable to shareholders dropped by 83.58% to CNY 1,232,673.76 compared to the same period last year[11] - The company reported a net profit of CNY 72,492,202.36, compared to CNY 71,259,528.60 in the previous period, reflecting a slight increase of approximately 1.73%[30] - Total operating revenue for Q1 2024 was ¥38,103,723.62, a decrease of 29.8% compared to ¥54,218,554.17 in Q1 2023[35] - Net profit for Q1 2024 was ¥1,232,673.76, a decline of 84.6% from ¥7,507,383.78 in Q1 2023[36] - Operating profit for Q1 2024 was ¥1,577,401.92, down 82.1% from ¥8,840,768.63 in Q1 2023[36] - The total profit for Q1 2024 was ¥1,671,902.92, a decrease of 81.1% from ¥8,870,768.63 in Q1 2023[36] Cash Flow - Cash flow from operating activities improved significantly, with a net cash flow of CNY -886,034.53, a 96.64% increase compared to the previous year[11] - Net cash flow from operating activities for Q1 2024 was -¥886,034.53, an improvement from -¥26,353,571.31 in Q1 2023[42] - Cash inflow from sales of goods and services for Q1 2024 was ¥40,168,247.17, an increase of 31% compared to ¥30,651,449.23 in Q1 2023[42] - Cash outflow from investment activities in Q1 2024 totaled ¥87,738,830.99, compared to ¥194,813,145.87 in Q1 2023, indicating a reduction of 55%[43] - Net cash flow from investment activities for Q1 2024 was -¥55,689,285.04, a decline from a positive cash flow of ¥32,843,959.43 in Q1 2023[43] - Cash inflow from financing activities in Q1 2024 was ¥14,817,153.87, down 54% from ¥32,236,371.82 in Q1 2023[43] - Net cash flow from financing activities for Q1 2024 was -¥27,006,398.53, compared to a positive cash flow of ¥24,363,359.99 in Q1 2023[43] - The ending balance of cash and cash equivalents for Q1 2024 was ¥37,068,157.66, a decrease from ¥113,257,353.03 in Q1 2023[43] - The company experienced a net decrease in cash and cash equivalents of ¥83,581,614.00 in Q1 2024, contrasting with an increase of ¥30,854,533.95 in Q1 2023[43] Assets and Liabilities - Total assets decreased by 8.32% to CNY 678,670,304.26 compared to the end of last year[11] - The company's asset-liability ratio decreased to 27.50% for the parent company and 27.82% for the consolidated entity[11] - Cash and cash equivalents decreased by 69.32% to CNY 37,068,157.66 due to payments for construction projects and increased short-term loan repayments[12] - Total current assets decreased from 264,771,495.21 to 198,770,709.24, a decline of approximately 25%[28] - Current liabilities decreased from CNY 237,902,009.73 to CNY 174,414,148.36, a reduction of about 26.69%[30] - Non-current liabilities decreased from CNY 14,016,573.88 to CNY 14,684,494.87, an increase of approximately 4.75%[30] - Total liabilities decreased from CNY 251,918,583.61 to CNY 189,098,643.23, a decline of around 25.00%[30] - Owner's equity increased from CNY 488,338,987.27 to CNY 489,571,661.03, a growth of approximately 0.25%[30] - The company’s total liabilities to equity ratio improved from 0.52 to 0.39, indicating a stronger financial position[30] Shareholder Information - The total number of unrestricted shares is 169,132,685, accounting for 65.36% of the total share capital[17] - The number of shares held by the controlling shareholder is 79,153,007, representing 30.59% of the total share capital[17] - The total share capital is 258,777,181 shares, with 10,526 common shareholders[17] - The largest shareholder, Renhe Real Estate Development Co., Ltd., holds 154,329,462 shares, which is 59.638% of the total[20] - The total number of shares held by the top ten shareholders is 175,431,286, accounting for 67.7923% of the total share capital[20] Inventory and Expenses - Inventory increased from 63,738,502.55 to 70,133,500.87, an increase of about 10.5%[28] - Research and development expenses for Q1 2024 were ¥1,238,549.82, slightly down from ¥1,286,808.01 in Q1 2023[35] - Sales expenses for Q1 2024 were ¥20,717,841.19, a decrease of 16.3% compared to ¥24,740,896.78 in Q1 2023[35] - The company experienced a significant increase in management expenses, which rose to ¥7,604,805.52 in Q1 2024 from ¥5,865,479.78 in Q1 2023[35] Other Information - The company has not reported any litigation or arbitration matters during the reporting period[24] - The company has initiated a share buyback plan, which has been disclosed in a timely manner[24] - The company reported a significant increase in asset impairment losses, which rose by 920.12% to CNY 167,601.38[13] - Non-recurring gains and losses totaled CNY 300,981.26, with a net amount after tax of CNY 257,367.02[15]